RESISTANCE RATES OF MYCOBACTERIUM TUBERCULOSIS COMPLEX ISOLATES OBTAINED FROM CLINICAL SAMPLES TO MAJOR ANTITUBERCULOUS DRUGS: A STUDY IN EDIRNE, TURKEY
PDF
Cite
Share
Request
Original Article
P: 28-31
June 2018

RESISTANCE RATES OF MYCOBACTERIUM TUBERCULOSIS COMPLEX ISOLATES OBTAINED FROM CLINICAL SAMPLES TO MAJOR ANTITUBERCULOUS DRUGS: A STUDY IN EDIRNE, TURKEY

Turk Med Stud J 2018;5(2):28-31
1. Trakya University School of Medicine, Edirne, TURKEY
2. Department of Microbiology, Trakya University School of Medicine, Edirne, TURKEY
No information available.
No information available.
Received Date: 09.04.2018
Accepted Date: 20.04.2018
PDF
Cite
Share
Request

ABSTRACT

Aims:

The aim of this study is to reveal the rates of the Mycobacterium tuberculosis complex resistance to major antituberculous drugs (streptomycin, isoniazid, rifampicin, ethambutol) by the evaluation of the specimens that are sent to Trakya University Hospital Microbiology Laboratory.

Methods:

In this study, laboratory data of the cases that were pre-diagnosed with tuberculosis between 11/02/2016 and 31/12/2017 were scanned retrospectively. To compare the annual data descriptive statistics as arithmetic mean, numbers and percentages were used.

Results:

Out of 4752 samples, 133 (2.79%) were culture positive. 120 isolates were identified as Mycobacterium tuberculosis complex, while other 13 were defined as Mycobacterium other than tuberculosis. Antimycobacterial susceptibility tests showed that 9 (7.5%) isolates were resistant to streptomycin, 10 (8.33%) isolates to isoniazid, 4 (3.33%) isolates to rifampicin, 4 (3.33) isolates to ethambutol. 5 (4.16%) isolates were multidrug resistant.

Conclusion:

Antituberculous drug resistance is still a threat for an effective treatment of tuberculosis and streptomycin resistance has increased. However, it is also pointed out that presence of Mycobacterium other than tuberculosis in isolates has increased.

Keywords: Drug resistance, tuberculosis, streptomycin

2024 ©️ Galenos Publishing House